Literature DB >> 21459722

Expression of HLA-G in patients with hepatocellular carcinoma.

Yan Wang1, Zhou Ye, Xue-Qin Meng, Shu-Sen Zheng.   

Abstract

BACKGROUND: Human leukocyte antigen G (HLA-G) is a non-classical major histocompatibility complex class I molecule that has multiple immune regulatory functions including the induction of immune tolerance. The detection of HLA-G expression might serve as a clinical marker in the prediction of clinical outcomes for certain types of carcinoma. Currently, we investigated whether or not HLA-G is also expressed in patients with hepatocellular carcinoma (HCC), and whether the expression has clinical value.
METHODS: Serum levels of secreted HLA-G (sHLA-G) were measured by ELISA in 36 patients with HCC, 25 patients with liver cirrhosis (LC) and 25 healthy individuals. The expression of HLA-G in liver tissue was further studied using Western blotting in 36 patients with HCC and 25 with LC. The correlations between HLA-G status and various clinicopathological parameters including survival were analyzed.
RESULTS: The ELISA assay showed that the serum levels of sHLA-G in the HCC, LC and healthy groups were 132.6+/-31.4, 63.5+/-22.1, and 47.0+/-15.5 U/ml, respectively. Analysis of variance was used for inter-group comparison and differences were found between the HCC group and the other two groups (both P<0.01), while no difference was found between the LC group and the healthy group (P=0.112). HLA-G protein expression in liver tissue was found in 66.7% (24/36) of the primary sites of HCC, but not in benign lesions (LC). Further, the HLA-G expression in tumors had no significant correlation with the parameters of age, gender, histological grade and alpha-fetoprotein level. However, patients with HLA-G-positive tumors had a shorter postoperative survival time than those with HLA-G-negative tumors (P=0.014). Also, univariate analysis showed that HLA-G was an independent prognostic factor.
CONCLUSION: Our results indicated that the expression of HLA-G was a characteristic feature of HCC and patients with positive expression of HLA-G in malignant liver tissue had a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21459722     DOI: 10.1016/s1499-3872(11)60025-8

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  18 in total

Review 1.  Cancer treatment and the KIR-HLA system: an overview.

Authors:  Patrizia Leone; Valli De Re; Angelo Vacca; Franco Dammacco; Vito Racanelli
Journal:  Clin Exp Med       Date:  2017-02-10       Impact factor: 3.984

2.  HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer.

Authors:  Li Zhou; Zhe-Yu Niu; Zhi-Yong Liang; Wei-Xun Zhou; Lei You; Meng-Yi Wang; Lu-Tian Yao; Quan Liao; Yu-Pei Zhao
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

3.  Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Mol Med       Date:  2015-08-24       Impact factor: 6.354

4.  Association of serum soluble human leukocyte antigen-G levels with chronic hepatitis B virus infection.

Authors:  Qunying Han; Na Li; Qianqian Zhu; Zhu Li; Guoyu Zhang; Jinghong Chen; Yi Lv; Yawen Wang; Zhengwen Liu; Chunqiu Hao
Journal:  Clin Exp Med       Date:  2012-09-25       Impact factor: 3.984

Review 5.  The Role of HLA-G Molecule and HLA-G Gene Polymorphisms in Tumors, Viral Hepatitis, and Parasitic Diseases.

Authors:  Fabrício C Dias; Erick C Castelli; Cristhianna V A Collares; Philippe Moreau; Eduardo A Donadi
Journal:  Front Immunol       Date:  2015-02-02       Impact factor: 7.561

Review 6.  Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

7.  Prognostic and Clinicopathological Value of Human Leukocyte Antigen G in Gastrointestinal Cancers: A Meta-Analysis.

Authors:  Yongjia Peng; Jian Xiao; Wenyun Li; Shuna Li; Binbin Xie; Jiang He; Chaoqun Liu
Journal:  Front Oncol       Date:  2021-05-12       Impact factor: 6.244

8.  The Potential of HLA-G-Bearing Extracellular Vesicles as a Future Element in HLA-G Immune Biology.

Authors:  Vera Rebmann; Lisa König; Fabiola da Silva Nardi; Bettina Wagner; Luis Felipe Santos Manvailer; Peter A Horn
Journal:  Front Immunol       Date:  2016-05-04       Impact factor: 7.561

9.  Human leukocyte antigen-G expression and polymorphisms promote cancer development and guide cancer diagnosis/treatment.

Authors:  Yanwen Zhang; Shuwen Yu; Yali Han; Yunshan Wang; Yuping Sun
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

Review 10.  HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.